News – Page 358 – Endpoints News

Applied Molecular Transport prepares to close up shop as it pauses R&D, replaces CEO, lays off 57%

3 years ago

Merck touts PhIII Keytruda data in frontline endometrial cancer

3 years ago

Esperion sues Daiichi Sankyo, demanding payment of $300M milestone for cardio drug

3 years ago

Heated oral arguments at SCOTUS hint at Sanofi-Regeneron edge over Amgen in patent spat

3 years ago

Merck KGaA takes back control of PD-L1 cancer drug as Pfizer alliance ends

3 years ago

Eli Lilly to increase investment to $1B into new Irish manufacturing facility — report

3 years ago

Senator asks FTC to investigate AmerisourceBergen over abortion pill distribution plans

3 years ago

Resilience notches $410M in federal financing to bolster production

3 years ago

BioNTech readies for plunge in Covid sales, will boost mRNA and oncology pipelines

3 years ago

Gamida Cell makes more staff cuts and restructures as it focuses on potential drug launch

3 years ago

Vertex ponies up $100M for CRISPR's gene editing tech to develop new diabetes modality

3 years ago

Jounce nixes Redx offer as I/O biotech instead goes with Concentra Biosciences’ takeover bid

3 years ago

Who’s spending and who’s cutting from Big Pharma’s $127B R&D budget? Here are the top 15 players

3 years ago

AstraZeneca, Ionis boast full PhIII win for ATTR drug under review

3 years ago

Codiak files for Chapter 11 bankruptcy as most executives head for the exit

3 years ago

Announcing three exciting journalists who are joining the Endpoints newsroom

3 years ago

Labviva nets $20M Series A to ease life science procurement process

3 years ago

With one of biotech's largest private rounds in a year, ArriVent enters PhIII

3 years ago

A career in cancer research turns out to be the perfect prep for a grueling personal adventure

3 years ago

Another biotech startup runs into a PhII pileup in Parkinson's

3 years ago

BrainStorm gets FDA adcomm for ALS drug after failed trial and RTF

3 years ago

Venture investing without the GSK tie-up? Simeon George and the SR One team score a $600M fund to pave the way ...

3 years ago

Latest on ultra-rare disease approval; Positive, if mixed, signs for Biogen's ALS drug; Clay Siegall finds a new job; ...

3 years ago

Updated: FDA approves Pharming drug for ultra-rare immunodeficiency disease

3 years ago

First page Previous page 355 356 357358359 360 361 Next page Last page